This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 5mg | $250 | To Be Confirmed |
| 10mg | $450 | To Be Confirmed |
| 25mg | $750 | To Be Confirmed |
| 50mg | $1250 | To Be Confirmed |
| 100mg | $1950 | To Be Confirmed |
| 250mg | $3800 | To Be Confirmed |
: Cat #: V3812 CAS #: 1613268-23-7 Purity ≥ 98%
Description: Taniborbactam (VNRX5133) is a novel, Phase 3-ready, reversible, selective, and injectable ß-lactamase inhibitor (BLI) that features uniquely potent and selective activity against both serine- and metallo-beta-lactamases. VNRX-5133 is under investigation in a fixed combination with the fourth generation cephalosporin, cefepime. Cefepime/VNRX-5133 may have the potential to provide a best-in-class broad-spectrum treatment option for infections due to carbapenem resistant pathogens including carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA), bioterror pathogens such as Burkholderia spp. and Salmonella spp. engineerable with serine- and metallo-beta-lactamases, and suspected polymicrobial infections caused by both gram-negative and gram-positive pathogens.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 389.26 |
|---|---|
| Molecular Formula | C19H28BN3O5 |
| CAS No. | 1613268-23-7 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: 10 mM |
| Water: N/A | |
| Ethanol: N/A | |
| Synonyms | VNRX-5133; VNRX5133; VNRX 5133 |
| Protocol | In Vitro | In vitro activity: Taniborbactam hydrochloride (VNRX-5133 hydrochloride) has IC50s of 0.5 nM, 2 nM, 0.5 nM, 0.06 nM for KPC-2, OXA-48, VIM-4 of K.pneumoniae strain and VIM-2 of P.aeruginosa strain. Both cefepime/Taniborbactam hydrochloride (10 μg/mL) and meropenem/Taniborbactam hydrochloride combinations are highly active against all six of the NDM-1-producing clinical isolates from K.pneumoniae and E.coli, with MIC ranges of 16-0.25 and 1-0.125 μg/mL, respectively. |
|---|---|---|
| In Vivo | A single dose of cefepime (32 mg/kg)/Taniborbactam hydrochloride (VNRX-5133 hydrochloride; 16 mg/kg; s.c.) achieves >4 log10 reduction in viable bacterial counts in the neutropenic mouse lung infection model against a CTX-M-14-producing strain of K.pneumoniae[2]. Combination of Cefepime (16 mg/kg) and Taniborbactam hydrochloride (16 mg/kg; s.c.; twice-a-day for 7 days) demonstrates >2 log10 reductions in viable bacterial counts in the kidney of the ascending urinary tract infection model against a CTX-M-15-producing strain of E.coli[2]. Taniborbactam hydrochloride has a T1/2 of 0.16 hours, a CL of 618 mL/h/kg, and a Vss of 143 mL/kg for mice. | |
| Animal model | Mouse |
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 2.5690 mL | 12.8449 mL | 25.6898 mL | 51.3795 mL |
| 5mM | 0.5138 mL | 2.5690 mL | 5.1380 mL | 10.2759 mL |
| 10mM | 0.2569 mL | 1.2845 mL | 2.5690 mL | 5.1380 mL |
| 20mM | 0.1284 mL | 0.6422 mL | 1.2845 mL | 2.5690 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.